Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | VP, Chief Commercial Officer | February 28, 2023 | March 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date February 28, 2023 · Filed March 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,136 |
Ending reported balance
After 2023-02-28 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-02-28 · Exercise / conversion · Acquired 14,833 · Balance 36,700 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2023-02-28 · Exercise / conversion · Acquired 5,286 · Balance 41,986 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 3 · 2023-02-28 · Exercise / conversion · Acquired 22,963 · Balance 64,949 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 4 · 2023-02-28 · Tax withholding · Disposed 11,813 · Balance 53,136 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-02-28 · Exercise / conversion · Disposed 14,833 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,287 |
Reported balance
After 2023-02-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-02-28 · Exercise / conversion · Disposed 5,286 · Balance 5,287 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 45,927 |
Reported balance
After 2023-02-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-02-28 · Exercise / conversion · Disposed 22,963 · Balance 45,927 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 22,963 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · derivative · entry 7 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,927 Underlying: Common Stock · 22,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 5,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · derivative · entry 6 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287 Underlying: Common Stock · 5,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 14,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · derivative · entry 5 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 11,813 | $2.17 | $25,634.21 |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · nonDerivative · entry 4 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,136 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 22,963 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · nonDerivative · entry 3 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 5,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · nonDerivative · entry 2 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 14,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007932 · form4.xml · nonDerivative · entry 1 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:04 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 280,100 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001127602-23-004944 · form4.xml · derivative · entry 2 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,100 Underlying: Common Stock · 280,100 shares Expires 2033-02-09 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:04 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 93,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004944 · form4.xml · derivative · entry 1 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,370 Underlying: Common Stock · 93,370 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 5,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · derivative · entry 7 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,573 Underlying: Common Stock · 5,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F4 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 14,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · derivative · entry 6 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,833 Underlying: Common Stock · 14,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F4 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 10,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · derivative · entry 5 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 8,261 | $2.85 | $23,543.85 |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · nonDerivative · entry 4 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,867 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 5,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · nonDerivative · entry 3 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 14,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · nonDerivative · entry 2 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 00:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 10,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-007175 · form4.xml · nonDerivative · entry 1 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 68,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004765 · form4.xml · derivative · entry 2 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,890 Underlying: Common Stock · 68,890 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 206,670 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001127602-22-004765 · form4.xml · derivative · entry 1 Seth Kiernan · CIK 0001890439 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,670 Underlying: Common Stock · 206,670 shares Expires 2032-02-10 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.